SCHEMBL26418207

SCHEMBL26418207

CC(C)C(=O)NCc1ccc(OC(=O)C(C)C)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 4/20 0.56
PRMT6 Q96LA8 4/20 0.56
ERCC1 P07992 1/20 0.54
ERCC4 Q92889 1/20 0.54
ALOX15 P16050 2/20 0.49
ADRB2 P07550 1/20 0.48
ADRA2A P08913 1/20 0.48
DRD2 P14416 1/20 0.48
ADRA2C P18825 1/20 0.48
DRD1 P21728 1/20 0.48
ADRA1A P35348 1/20 0.48
DRD3 P35462 1/20 0.48
PTGES O14684 1/20 0.45
SMO Q99835 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
FAAH O00519 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23417897 0.89 CARM1 (0.56) CARM1PRMT6ERCC1ERCC4PTGES
SCHEMBL29344009 0.88 CARM1 (0.49) CARM1PRMT6ERCC1ERCC4ALOX15
SCHEMBL26418208 0.82 ERCC1 (0.47) CARM1PRMT6ERCC1ERCC4ALOX15
SCHEMBL14368078 0.81 ERCC1 (0.64) CARM1PRMT6ERCC1ERCC4PTGES
SCHEMBL24668212 0.80 ALOX15 (0.54) CARM1PRMT6ALOX15ADRB2ADRA2A
SCHEMBL14573639 0.79 ERCC1 (0.60) CARM1PRMT6ERCC1ERCC4PTGES
SCHEMBL26428983 0.77 ADRB2 (0.50) CARM1PRMT6ALOX15ADRB2ADRA2A
SCHEMBL22059482 0.77 ERCC1 (0.59) CARM1PRMT6ERCC1ERCC4PTGES
SCHEMBL26418205 0.77 ERCC1 (0.54) CARM1PRMT6ERCC1ERCC4MEN1
SCHEMBL28177057 0.75 CARM1 (0.56) CARM1PRMT6ERCC1ERCC4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238436-A1 COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-07-18 US disclosed
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES CD2BP2, CD2, CD47 CARM1 802/4885PRMT6 154/4885ERCC1 3649/4885
US-20240238436-A1 COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS LGMN, LPXN, LY96 CARM1 1110/4885PRMT6 1874/4885ERCC1 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.